{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/prescribing-information/pregabalin/","result":{"pageContext":{"chapter":{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin","depth":2,"htmlHeader":"<!-- begin field 883c4bd0-3cd9-480b-ae29-34d8d556a712 --><h2>Pregabalin</h2><!-- end field 883c4bd0-3cd9-480b-ae29-34d8d556a712 -->","summary":"","htmlStringContent":"<!-- begin item a7d24a97-8d74-4f0b-af5c-d73c8312410e --><!-- end item a7d24a97-8d74-4f0b-af5c-d73c8312410e -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"94522f6d-2f25-59ba-8ad5-baa5758c67e7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fdf3b527-2794-4a17-a569-29cefcbf3071 --><h3>Contraindications and cautions of pregabalin</h3><!-- end field fdf3b527-2794-4a17-a569-29cefcbf3071 -->","summary":"","htmlStringContent":"<!-- begin item febcb945-b175-466a-b760-aee677972d04 --><!-- begin field 39fe0e09-24f3-4321-b811-199d1b0c7ddc --><p><strong>Prescribe pregabalin with caution to people:</strong></p><ul><li>With renal impairment — a reduced initial and maximum daily dosage is recommended. For more information, see the section on dose<a class=\"topic-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/prescribing-information/pregabalin/#dose-titration\"> and titration</a>.</li><li>At risk of encephalopathy — cases of encephalopathy have been reported, mostly in people with underlying conditions that may precipitate the condition.</li><li>With diabetes — pregabalin may cause weight gain. People with diabetes who gain weight on pregabalin may need to adjust their anti-diabetic medication.</li><li>At risk of falls (such as older people) — pregabalin has been associated with dizziness and somnolence, and there have been post-marketing reports of loss of consciousness, confusion, and mental impairment.</li><li>At risk of cardiovascular compromise — due to the risk of congestive heart failure. Discontinue if the person develops symptoms of heart failure (such as breathlessness, fatigue, and ankle swelling) or worsening of heart failure.</li><li>At risk of suicide — there is a small increased risk of suicidal ideation and behaviour in people treated with antiepileptic drugs. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for pregabalin.<ul><li>Monitor at-risk people for <a class=\"topic-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/management/management/#risk-of-suicide\">signs of suicidal ideation</a>.</li></ul></li><li>Using medications that can cause constipation (such as opioids) — there are post-marketing reports of events related to reduced lower gastrointestinal tract function (such as intestinal obstruction, paralytic ileus, and constipation) when pregabalin was co-administered with such medications. <ul><li>During combination therapy, measures to prevent constipation should be considered, especially in women and older people.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field 39fe0e09-24f3-4321-b811-199d1b0c7ddc --><!-- end item febcb945-b175-466a-b760-aee677972d04 -->","subChapters":[]},{"id":"eead689a-76b5-59b6-9312-23fa3f93b2f1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7359f7a2-b843-489b-8c9d-22ab0a831fc2 --><h3>What are the adverse effects of pregabalin?</h3><!-- end field 7359f7a2-b843-489b-8c9d-22ab0a831fc2 -->","summary":"","htmlStringContent":"<!-- begin item 875f84ca-5d0d-4780-b541-f456d4fedc64 --><!-- begin field 98f63338-156e-45c1-bb51-1893cb5acc76 --><p><strong>Adverse effects of pregabalin include:</strong></p><ul><li><strong>CNS effects </strong>—<strong> </strong>such as<strong> </strong>dizziness, somnolence, headache, ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, inattention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy.</li><li><strong>Increased appetite and weight gain.</strong> </li><li><strong>Psychiatric effects </strong>— such as euphoria, confusion, irritability, disorientation, insomnia, suicidal thoughts and behaviour.</li><li><strong>Sexual dysfunction</strong> — such as decreased libido, erectile dysfunction.</li><li><strong>Gastrointestinal effects</strong> — such as vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth.</li><li><strong>Ocular effects</strong> — such as blurred vision and diplopia.</li><li><strong>Musculoskeletal and connective tissue effects </strong>— such as muscle cramp, arthralgia, back pain, limb pain, cervical spasm.</li><li><strong>Respiratory effects</strong> — severe respiratory depression.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2020c</a>]</p><!-- end field 98f63338-156e-45c1-bb51-1893cb5acc76 --><!-- end item 875f84ca-5d0d-4780-b541-f456d4fedc64 -->","subChapters":[]},{"id":"f5d89cb1-22e6-5d6a-834a-f8995612092e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4f34dd88-4002-4bd2-879e-a3a33579c71c --><h3>What are the key drug interactions with pregabalin?</h3><!-- end field 4f34dd88-4002-4bd2-879e-a3a33579c71c -->","summary":"","htmlStringContent":"<!-- begin item d102b2ae-57fc-4bee-8767-a099d8ad27ae --><!-- begin field c42cce52-a49f-4500-bd74-cced7f9be9e5 --><ul><li>Pregabalin has no clinically important pharmacokinetic drug interactions. However:<ul><li>There may be additive sedative effects if pregabalin is used with other central nervous system depressants (such as alcohol and benzodiazepines).</li><li>Pregabalin used alongside opioid analgesics may cause reduced lower gastrointestinal tract function, leading to intestinal obstruction, paralytic ileus, and/or constipation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017f</a>]</p><!-- end field c42cce52-a49f-4500-bd74-cced7f9be9e5 --><!-- end item d102b2ae-57fc-4bee-8767-a099d8ad27ae -->","subChapters":[]},{"id":"7058b005-6972-502f-9207-dbb2eb3a3f0d","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 57911bde-20bd-483e-91da-5bb63afee49a --><h3>What dose of pregabalin should I prescribe and how should I titrate the dose?</h3><!-- end field 57911bde-20bd-483e-91da-5bb63afee49a -->","summary":"","htmlStringContent":"<!-- begin item 57b18960-2bfb-4a4a-b3b7-43891ab5c511 --><!-- begin field d1f81687-549f-46db-a970-031470dd9bd7 --><ul><li>Start treatment at 150 mg daily (in two to three divided doses). If required, increase in steps of 150 mg daily at seven-day intervals. Maximum dose 600 mg daily in two to three divided doses.</li><li>A lower starting dose may be appropriate for people with reduced renal function. Please see table 1 for further details.</li><li>Seek specialist advice and consult the manufacturer's Summary of Product Characteristics for people undergoing haemodialysis.</li></ul><p><strong>Table 1. </strong>Recommended dosages of pregabalin based on renal function.</p><table data-table-id=\"8b3cb483-3ccc-4817-9079-acce014ec46c\"><thead><tr><th colspan=\"1\"><p>Creatinine clearance (CLcr)</p><p>(mL/min)</p></th><th colspan=\"1\">Starting daily dose</th><th colspan=\"1\">Maximum daily dose</th></tr></thead><tbody><tr><td colspan=\"1\">≥ 60</td><td colspan=\"1\"> 150 mg (divided in two or three doses)</td><td colspan=\"1\">600 mg (divided in two or three doses)</td></tr><tr><td colspan=\"1\">≥30 to <60</td><td colspan=\"1\">75mg (divided in two or three doses)</td><td colspan=\"1\">300 mg (divided in two or three doses)</td></tr><tr><td colspan=\"1\">≥15  to  <30</td><td colspan=\"1\">25 to 50 mg (divided in one or two doses)</td><td colspan=\"1\">150 mg (divided in one or two doses)</td></tr><tr><td colspan=\"1\">< 15</td><td colspan=\"1\">25 mg once daily</td><td colspan=\"1\">75 mg once daily</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field d1f81687-549f-46db-a970-031470dd9bd7 --><!-- end item 57b18960-2bfb-4a4a-b3b7-43891ab5c511 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}